John L Lamattina sold $434K of Ligand Pharmaceuticals Incorporated (LGND)

Executed Mar 6, disclosed Mar 31, 25 days later, against a two-business-day limit.

Value, as filed

$434K

2,161 sh × $200.76

Executed

Mar 6

the trade date, as filed

Disclosed

Mar 31

25 days after the trade · past the deadline

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

John L Lamattina Director profile →

John L Lamattina (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales, 1 filed past the two-business-day deadline), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.0M of LGND (4,102 sh across 2 lots, as filed), executed Jun 10.

The name

LGND

Ligand Pharmaceuticals Incorporated LGND · Healthcare · 36 filings in 24 months ticker →

Healthcare · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by John L Lamattina in LGND

LGNDSALE Ligand Pharmaceuticals Incorporated $1.0M
4,102 sh across 2 lots
Exec Jun 10
Filed Jun 12 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $859K
4,179 sh across 2 lots
Exec Nov 7 2025
Filed Nov 12 2025 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $298K
2,406 sh × $123.65
Exec Nov 27 2024
Filed Dec 2 2024 · 5:30 PM ET